Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sunshine Biopharma Inc. (NASDAQ: SBFM) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Sunshine Biopharma’s pharmaceutical and biotechnology operations, corporate governance, and financial reporting, complementing its public news releases about generics, biosimilars, and proprietary drug development.
Investors can review current reports on Form 8-K, where Sunshine Biopharma reports material events. Recent 8-K filings describe matters such as the dismissal of Bush & Associates CPA LLC as the company’s independent registered public accounting firm, the engagement of M&K CPAS, PLLC as its new auditor, and the outcomes of the annual meeting of stockholders. The December 2025 Form 8-K, for example, details the election of directors, ratification of M&K CPAS, PLLC for the 2025 audit year, and stockholder approval of an amendment to the 2023 Equity Incentive Plan to increase the number of shares authorized for issuance.
The platform also surfaces Sunshine Biopharma’s Definitive Proxy Statements on Schedule 14A, which outline proposals submitted to shareholders, board composition, corporate governance practices, executive compensation information, and procedures for the annual meeting. These filings help readers understand how the company is managed and how key decisions—such as equity incentive plan changes or auditor selection—are presented to and approved by shareholders.
On Stock Titan, Sunshine Biopharma’s 10-K annual reports, 10-Q quarterly reports, proxy statements, and 8-K current reports are supplemented with AI-powered summaries that explain complex sections in plain language. Users can quickly identify disclosures related to revenue sources, generic and biosimilar activities, research and development commitments, auditor changes, and equity incentive plans without reading every page. Real-time updates from EDGAR ensure that new filings, including any future Forms 4 reporting insider transactions, appear promptly, while AI-generated highlights point to sections that may be most relevant for analysis.
By using this filings page, investors, analysts, and researchers can efficiently review Sunshine Biopharma’s regulatory history, track governance and accounting developments, and connect formal SEC disclosures with the company’s broader strategy in generics, biosimilars, mRNA cancer therapies, and antiviral drug development.
Sunshine Biopharma Inc. is informing holders that on
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. notified holders that the holder of approximately 96.4% voting power, Dr. Steve N. Slilaty, approved by written consent an amendment to permit a reverse stock split of the common stock by a ratio of up to 1-for-10, with the Board having sole discretion whether to implement the split and to set the exact whole-number ratio up to 1-for-10.
As of February 18, 2026, the company had 4,905,945 shares outstanding; at a 1-for-10 split that figure would become 490,595 shares (fractional shares rounded up). The stated purpose is to address Nasdaq’s $1.00 minimum bid-price requirement; effectiveness requires filing the amendment with the Colorado Secretary of State.
Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.
Sunshine Biopharma Inc. reported the results of its annual stockholder meeting held on December 11, 2025. Stockholders elected five directors — including Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller — to serve until the next annual meeting or until successors are elected and qualified.
Shareholders also ratified the appointment of M&K CPAS, PLLC as the company’s independent registered public accounting firm for 2025. In addition, they approved an amendment to the 2023 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan to 683,000, providing additional equity available for future employee and director compensation awards.
Sunshine Biopharma (SBFM) filed its Q3 2025 10‑Q, highlighting year‑over‑year revenue growth and a smaller quarterly loss. Revenue for the quarter reached $9,417,179, up 11.6% from a year ago, with gross profit of $3,073,540. Operating loss was $1,086,613, and net loss narrowed to $883,820, or $0.19 per share.
For the nine months ended September 30, 2025, revenue was $27,728,750 (up 9.7%). Net loss for the period was $3,834,425, reflecting higher G&A and a $1,616,459 impairment of intangible assets tied to product licenses that could not be commercialized. Cash and equivalents were $9,306,438 as of September 30, 2025.
The company completed an April 2025 registered direct offering, receiving $1,828,596 in net proceeds, and reported additional cash from warrant exercises during the year. Shares outstanding were 4,555,945 as of September 30, 2025, and 4,905,945 as of November 13, 2025. Management aims to reduce cost of goods sold toward 60% to move toward breakeven while continuing to expand Nora Pharma’s Canadian generic portfolio.
Sunshine Biopharma (SBFM) will hold its 2025 virtual annual meeting on December 11, 2025 to vote on three items: elect five directors, ratify M&K CPAS, PLLC as auditor, and amend the 2023 Equity Incentive Plan to increase shares authorized for issuance from 1,661 to 683,000.
The record date is October 17, 2025, with 4,905,945 common shares and 130,000 Series B Preferred outstanding. Each Series B Preferred share carries 1,000 votes, and all Series B shares are held by the CEO, concentrating voting power. The Board recommends voting FOR all proposals.
Auditor history was addressed: following the SEC’s settled order permanently barring BF Borgers from practicing before the SEC, the company dismissed Borgers in 2024, engaged Bush & Associates, and on September 24, 2025 appointed M&K CPAS, PLLC. Executive agreements disclose severance terms, including
Sunshine Biopharma Inc. reported a change in its independent auditor. Effective September 24, 2025, the company dismissed Bush & Associates CPA LLC as its independent registered public accounting firm and engaged M&K CPAS, PLLC as its new auditor. The board of directors and audit committee approved this decision by unanimous consent.
The company states that for the fiscal years ended December 31, 2023 and 2024, and through September 24, 2025, there were no disagreements with Bush & Associates on accounting principles, financial statement disclosure, or audit procedures, and no reportable events under SEC rules. Bush & Associates’ prior audit reports did not contain adverse opinions, disclaimers, or qualifications. Sunshine Biopharma has requested a letter from Bush & Associates to the SEC regarding these disclosures and plans to file it by amendment once received.